Cargando…

Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience

AIM: To explore and compare the efficacy of standard (300 mg every 2 weeks) and extended (300 mg every 4 weeks) dosing regimens of lanadelumab for long-term prophylaxis of hereditary angioedema (HAE). METHODS: We conducted a retrospective chart review of all patients with HAE on lanadelumab, which i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abuzakouk, Mohamed, Ghorab, Omar, Al-Hameli, Hamad, Salvo, Fulvio, Grandon, Deepa, Maurer, Marcus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Allergy Organization 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287634/ https://www.ncbi.nlm.nih.gov/pubmed/35891672 http://dx.doi.org/10.1016/j.waojou.2022.100664

Ejemplares similares

Lanadelumab for hereditary angioedema
Publicado: (2022)

Long-term prophylaxis for hereditary angioedema: Initial experiences with garadacimab and lanadelumab
por: Wong, Jane C.Y., et al.
Publicado: (2023)

Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema
por: Wang, Yi, et al.
Publicado: (2020)

Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study
por: Banerji, Aleena, et al.
Publicado: (2021)

Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
por: Johnston, Douglas T., et al.
Publicado: (2021)

Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
por: Lumry, William R., et al.
Publicado: (2020)

Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada
por: Iaboni, Aled, et al.
Publicado: (2021)

Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema
por: Watt, Maureen, et al.
Publicado: (2023)

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy
por: Bova, Maria, et al.
Publicado: (2019)

Experience of lanadelumab administration in hereditary angioedema: A case series of 4 patients in Portugal
por: Bernardino, Ana Graça, et al.
Publicado: (2023)

Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights
por: Petkova, Elena, et al.
Publicado: (2022)

Successful use of lanadelumab in a patient with hereditary angioedema with normal C1 inhibitor and negative genetic testing
por: Adatia, Adil, et al.
Publicado: (2023)

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018)

Effectiveness and safety of lanadelumab in ethnic and racial minority subgroups of patients with hereditary angioedema: results from phase 3 studies
por: Craig, Timothy J., et al.
Publicado: (2022)

Efficacy and Safety of Biologic Agents in Chronic Urticaria, Asthma and Atopic Dermatitis – A Real-life Experience
por: Abuzakouk, Mohamed, et al.
Publicado: (2020)

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension
por: Riedl, Marc A., et al.
Publicado: (2017)

Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report
por: Burns, Stephanie, et al.
Publicado: (2021)

Informed decision‐making in hereditary angioedema prophylaxis
por: Burnette, Autumn Ford
Publicado: (2021)

Long-term prophylaxis of hereditary angioedema with danazol
por: Xu, Yingyang, et al.
Publicado: (2022)

Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France
por: Fain, Olivier, et al.
Publicado: (2022)

Consensus on diagnosis and management of Hereditary Angioedema in the Middle East: A Delphi initiative
por: Maurer, Marcus, et al.
Publicado: (2022)

Hereditary Angioedema Type II: First Presentation in Adulthood with Recurrent Severe Abdominal Pain
por: Abuzakouk, Mohamed, et al.
Publicado: (2018)

Hereditary angioedema
por: Lesser, Helen, et al.
Publicado: (2021)

Hereditary Angioedema
por: Banerjee, Anjali, et al.
Publicado: (2023)

Hereditary angioedema patients would prefer newer-generation oral prophylaxis
por: Geba, Daniela, et al.
Publicado: (2021)

Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema
por: Gower, Richard G., et al.
Publicado: (2021)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
por: Guo, Yinshi, et al.
Publicado: (2022)

Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe
por: Zanichelli, Andrea, et al.
Publicado: (2013)

Hereditary angioedema in women
por: Bouillet, Laurence
Publicado: (2010)

Hereditary Angioedema: Not An Allergy
por: Bhivgade, Sanjay, et al.
Publicado: (2012)

The Pathophysiology of Hereditary Angioedema
por: Zuraw, Bruce L
Publicado: (2010)

Pediatric hereditary angioedema
por: MacGinnitie, Andrew J
Publicado: (2014)

Hereditary angioedema in childhood
por: Ahn, Young Min
Publicado: (2020)

Biomarkers in Hereditary Angioedema
por: Porebski, Grzegorz, et al.
Publicado: (2021)

A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
por: Aygören‐Pürsün, Emel, et al.
Publicado: (2019)

Reviewing clinical considerations and guideline recommendations of C1 inhibitor prophylaxis for hereditary angioedema
por: Anderson, John, et al.
Publicado: (2022)

Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape
por: Soteres, Daniel F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_258a9e1jgthdj8tiv46n3417ck